CYP19A1 and breast cancer: Previous studies also revealed that breast cancer patients undergoing endocrine therapy experienced a range of emotional distress (11, 38) The widely used endocrine treatment reduces the postmenopausal estrogen levels by nearly complete inhibition of the enzyme aromatase or anti-estrogenic effects on breast cancer cells that contain estrogen receptors by blocking this receptor (3).